Advances in the Treatment of Systemic Sclerosis

Although systemic sclerosis (SSc) is currently incurable, there have been recent advances in treatment. This review article begins by providing a brief background to SSc terms of disease subtyping and autoantibodies, because both predict trajectory help clinicians select appropriate monitoring treatment protocols. Broad principles management are then described: ‘disease-modifying’ therapies directed at reducing burden and/or progression SSc-related digital vascular internal organ involvement. Next, the vasculopathy, pulmonary arterial hypertension (PAH), interstitial lung (ILD) early diffuse cutaneous discussed turn, for example: (a) increased use phosphodiesterase inhibitors endothelin receptor antagonists vasculopathy; (b) recognition PAH, including with combination therapies; (c) mycophenolate mofetil nintedanib ILD; (d) immunosuppression now as standard practice SSc, autologous haematopoietic stem cell transplantation highly selected patients progressive disease. Finally, future challenges discussed, ensuring that all monitored treated according best guidelines, whenever possible giving opportunity participate clinical trials.